$ANIK

Fischetti Gary P purchased $41K of ANIK

Fischetti Gary P purchased 2,000 shares of Anika Therapeutics, Inc. (ANIK) at an average of $20.53 ($20.32–$20.74) across 2 trades over 2026-08-03 to 2026-08-04.

Original reporting
SEC EDGAR · Fischetti Gary P
Published Aug 5, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 6:26 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ANIK
Neutral
low confidence
Mentioned
$ANIK
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ANIKNeutralLow
01

Why it matters

The newest information is the director’s open-market purchase details (2,000 shares at ~$20.53 average) filed on 2026-08-05.

02

Market read

Traders may note the insider buy, but the disclosed dollar amount is modest and lacks accompanying operational catalysts.

03

What to watch

No 10b5-1 plan is cited, but the article also provides no context on prior insider activity, option exercises, or whether the director has a pattern of buys/sells.

Relevance 4/10Novelty 3/10Timing: Filed on 2026-08-05, covering purchases dated 2026-08-03 to 2026-08-04.

Background

This is a SEC Form 4 insider transaction disclosure for Anika Therapeutics, Inc.

Company-level read

Ticker impact

$ANIKNeutralLow confidence
Context

Anika Therapeutics director Fischetti Gary P bought 2,000 shares in open-market trades for about $41,060, per a new Form 4 filing.

Expected impact

Limited near-term impact; any effect is likely sentiment-only and short-lived.

Evidence & confidence

Form 4 insider purchases can signal confidence, but the disclosed size ($41k) and lack of 10b5-1 plan details provide weak signal strength versus earnings, guidance, or clinical/regulatory updates.

Market effects

No broader sector read-through is provided beyond a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

The purchase may reflect routine compensation or personal liquidity needs rather than a strong forward-looking view.

Key entities

  • Anika Therapeutics, Inc.

    Company whose director insider purchase is disclosed on Form 4.

  • Fischetti Gary P

    Director who purchased 2,000 shares in open-market trades.

Related articles

$ANIKMed

Anika Therapeutics, Inc. Q2 2026 Earnings Call Summary

Strategic Execution and Operational Drivers Achieved record commercial channel revenue growth of 17%, fueled by focused portfolio alignment and strong international demand for CINGAL and MONOVISC. Expanded gross margins to 65% by implementing a lean transformation that doubled throughput on key manufacturing lines and improved production yields.

$ANIKMed

Anika Therapeutics, Inc. (ANIK): Results of Operations and Financial Condition

Anika Therapeutics, Inc. (ANIK) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling EXHIBIT 99.1 Anika Reports Second Quarter 2026 Financial Results Commercial Channel Revenue Increased 17% to a Record $13.9 Million Delivered $3.3 Million of Net Income, 65% Gross Margin, and $7.1 Million of Adjusted EBITDA, Highest